Characterization of the Cynomolgus Macaque Model of Marburg Virus Disease and Assessment of Timing for Therapeutic Treatment Testing.

Marburg virus animal model animal rule cynomolgus macaque filovirus intramuscular nonhuman primate pathogenesis telemetry

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
28 Nov 2023
Historique:
received: 31 10 2023
revised: 15 11 2023
accepted: 16 11 2023
medline: 23 12 2023
pubmed: 23 12 2023
entrez: 23 12 2023
Statut: epublish

Résumé

Marburg virus (MARV) causes severe disease and high mortality in humans. The objective of this study was to characterize disease manifestations and pathogenesis in cynomolgus macaques exposed to MARV. The results of this natural history study may be used to identify features of MARV disease useful in defining the ideal treatment initiation time for subsequent evaluations of investigational therapeutics using this model. Twelve cynomolgus macaques were exposed to a target dose of 1000 plaque-forming units MARV by the intramuscular route, and six control animals were mock-exposed. The primary endpoint of this study was survival to Day 28 post-inoculation (PI). Anesthesia events were minimized with the use of central venous catheters for periodic blood collection, and temperature and activity were continuously monitored by telemetry. All mock-exposed animals remained healthy for the duration of the study. All 12 MARV-exposed animals (100%) became infected, developed illness, and succumbed on Days 8-10 PI. On Day 4 PI, 11 of the 12 MARV-exposed animals had statistically significant temperature elevations over baseline. Clinically observable signs of MARV disease first appeared on Day 5 PI, when 6 of the 12 animals exhibited reduced responsiveness. Ultimately, systemic inflammation, coagulopathy, and direct cytopathic effects of MARV all contributed to multiorgan dysfunction, organ failure, and death or euthanasia of all MARV-exposed animals. Manifestations of MARV disease, including fever, systemic viremia, lymphocytolysis, coagulopathy, and hepatocellular damage, could be used as triggers for initiation of treatment in future therapeutic efficacy studies.

Identifiants

pubmed: 38140576
pii: v15122335
doi: 10.3390/v15122335
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : t Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)
ID : W81XWH-16-0472

Auteurs

Elizabeth E Zumbrun (EE)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Carly B Garvey (CB)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Geneva Foundation, Tacoma, WA 98402, USA.

Jay B Wells (JB)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Geneva Foundation, Tacoma, WA 98402, USA.

Ginger C Lynn (GC)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Geneva Foundation, Tacoma, WA 98402, USA.

Sean Van Tongeren (S)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Geneva Foundation, Tacoma, WA 98402, USA.

Jesse T Steffens (JT)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Geneva Foundation, Tacoma, WA 98402, USA.

Kelly S Wetzel (KS)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Geneva Foundation, Tacoma, WA 98402, USA.

Laura M Gomba (LM)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Geneva Foundation, Tacoma, WA 98402, USA.

Kristan A O'Brien (KA)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Geneva Foundation, Tacoma, WA 98402, USA.

Franco D Rossi (FD)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Xiankun Zeng (X)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Eric D Lee (ED)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Jo Lynne W Raymond (JLW)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Diana A Hoffman (DA)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Alexandra N Jay (AN)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Elizabeth S Brown (ES)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Geneva Foundation, Tacoma, WA 98402, USA.

Paul A Kallgren (PA)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Sarah L Norris (SL)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Jean Cantey-Kiser (J)

PharPoint, Wilmington, NC 28405, USA.

Humza Kudiya (H)

Gilead Sciences, Foster City, CA 94404, USA.

Chris Arthur (C)

Gilead Sciences, Foster City, CA 94404, USA.

Christiana Blair (C)

Gilead Sciences, Foster City, CA 94404, USA.

Darius Babusis (D)

Gilead Sciences, Foster City, CA 94404, USA.

Victor C Chu (VC)

Gilead Sciences, Foster City, CA 94404, USA.

Bali Singh (B)

Gilead Sciences, Foster City, CA 94404, USA.

Roy Bannister (R)

Gilead Sciences, Foster City, CA 94404, USA.

Danielle P Porter (DP)

Gilead Sciences, Foster City, CA 94404, USA.

Tomas Cihlar (T)

Gilead Sciences, Foster City, CA 94404, USA.

John M Dye (JM)

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Classifications MeSH